[FBIO] Fortress Biotech, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.37 Change: 0.15 (6.76%)
Ext. hours: Change: 0 (0%)

chart FBIO

Refresh chart

Strongest Trends Summary For FBIO

FBIO is in the medium-term up 40% in 6 months. In the long-term down -64% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities9.36 M Cash From Investing Activities-1.36 M Cash From Operating Activities-8.83 M Gross Profit
Net Profit-12.06 M Operating Profit-12.07 M Total Assets90.45 M Total Current Assets69.61 M
Total Current Liabilities5.93 M Total Debt24.01 M Total Liabilities30.3 M Total Revenue500 K
Technical Data
High 52 week2.47 Low 52 week0.57 Last close1.3 Last change1.56%
RSI42.86 Average true range0.09 Beta1.27 Volume144.58 K
Simple moving average 20 days-8.19% Simple moving average 50 days-17.85% Simple moving average 200 days-21.32%
Performance Data
Performance Week4% Performance Month-32.29% Performance Quart-5.11% Performance Half-9.09%
Performance Year0% Performance Year-to-date51.16% Volatility daily3.6% Volatility weekly8.05%
Volatility monthly16.49% Volatility yearly57.12% Relative Volume321.39% Average Volume317.04 K
New High New Low

News

2020-05-26 21:30:10 | Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

2020-05-22 08:30:10 | Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders

2020-05-12 08:00:10 | Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

2020-05-12 07:51:44 | Is Fortress Biotech, Inc.'s NASDAQ:FBIO CEO Pay Justified?

2020-05-11 16:30:10 | Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

2020-05-11 16:20:10 | Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

2020-05-11 07:30:10 | Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

2020-05-08 07:30:10 | Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

2020-05-06 16:30:10 | Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

2020-04-30 07:30:10 | INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Fortress Biotech, Inc. for Potential Breach of Fiduciary Duty Claims.

2020-04-23 08:30:10 | Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

2020-04-21 08:00:10 | Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab

2020-04-20 08:00:10 | Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

2020-03-30 07:30:10 | Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights

2020-03-23 09:20:10 | Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program

2020-03-18 06:39:22 | Analysts Are Upgrading Fortress Biotech, Inc. After Its Latest Results

2020-03-16 16:45:10 | Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights

2020-03-16 16:45:10 | Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

2020-03-11 16:15:10 | Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

2020-02-24 08:00:10 | Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option

2020-02-18 08:00:10 | Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106

2020-02-13 08:00:10 | Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

2020-02-11 20:00:10 | Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

2020-01-22 08:30:10 | Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

2020-01-17 08:07:09 | The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

2020-01-17 07:23:26 | Loss-Making Fortress Biotech, Inc. NASDAQ:FBIO Expected To Breakeven

2020-01-16 08:30:10 | Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

2020-01-13 08:15:10 | Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

2020-01-13 07:30:10 | Journey Medical Corporation Recaps 2019 Growth

2019-12-23 08:30:10 | Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

2019-12-16 07:28:42 | Hedge Funds Have Never Been This Bullish On Fortress Biotech Inc FBIO

2019-12-11 08:30:10 | Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

2019-12-09 07:30:10 | Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency

2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

2019-12-02 08:30:10 | Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

2019-12-02 08:30:10 | Fortress Biotech to Participate in December 2019 Investor Conferences

2019-12-01 09:30:15 | The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

2019-11-25 20:00:10 | Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

2019-11-20 09:20:00 | Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

2019-11-19 16:01:00 | Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

2019-11-14 08:30:00 | Fortress Biotech Ranked in Top 10 of Deloitte’s 2019 Technology Fast 500™

2019-11-12 07:30:00 | Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-11-12 07:30:00 | Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-11-10 09:16:08 | Do Insiders Own Shares In Fortress Biotech, Inc. NASDAQ:FBIO?

2019-11-08 07:30:00 | Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer SITC Annual Meeting

2019-11-07 16:30:00 | Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-11-06 09:15:00 | Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

2019-11-04 07:30:00 | Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-10-28 08:30:05 | Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

2019-10-24 08:30:05 | Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 Oncolytic Virus C134 to Treat Glioblastoma